LOUISVILLE, Ky. / Apr 08, 2024 / Business Wire / Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, announced the release of its 2023 Impact Report, which includes details on the company’s continued commitment to improving the health outcomes for all as the foundation of its Environmental, Social and Governance (ESG) impact platform. The Impact Report covers Humana’s economic, social and environmental impacts in 2023, highlighting the company’s efforts to inspire and prioritize well-being among people, communities, the healthcare system and the environment.
“We’re committed to making the healthcare system more equitable, affordable and easier to navigate,” said Bruce Broussard, Humana’s Chief Executive Officer. “Healthcare is more than a service—it's an important journey that puts health first for every person who has entrusted us with their care.”
Humana reports and measures its performance in 5 key categories that support and shape its ESG platform: access to healthcare, data privacy and protection, environmental impact, product quality and safety, and talent and diversity. These qualitative and quantitative factors track, measure and report enterprise performance in achieving strategic business goals, supporting sustainable practices and improving health outcomes.
Some of Humana’s 2023 impact highlights include:
Humana will continue to provide transparency in all future reporting around continued Environmental, Social and Governance practices, processes, and metrics that connect to the business strategy. Future annual impact reports and the Humana website will feature updates.
To learn more about Humana’s impact and continuing work to make it easier for people to achieve their best health, read the full 2023 Humana Impact Report.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we strive to make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Last Trade: | US$293.97 |
Daily Change: | 16.19 5.83 |
Daily Volume: | 2,221,854 |
Market Cap: | US$35.400B |
November 12, 2024 October 30, 2024 October 24, 2024 October 23, 2024 August 19, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB